Absci Corp — Investor Relations & Filings
Filings indexed
315
across all filing types
Latest filing
2026-04-22
Annual Report
Country
US
United States of America
Listing
US
ABSI
Absci Corp. is a generative AI drug creation company focused on developing biologic medicines. The company's Integrated Drug Creation Platform combines artificial intelligence with scalable wet lab technologies to design and validate novel therapeutics. This platform operates through iterative cycles of data generation, AI model training, de novo design of biologics like antibodies, and experimental validation. Absci's capabilities also include AI-enabled target discovery using a proprietary 'Reverse Immunology' approach. As a clinical-stage company, it advances an internal pipeline and collaborates with pharmaceutical partners to accelerate the development of differentiated biologics for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | |
| SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 35398073 | ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | ||
| 33052408 | SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33048944 | SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33035253 | S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 33035179 | 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 32896336 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896337 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896338 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-25 | English | ||
| 32896339 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 32896340 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 31233301 | 4 Filing | 2026-02-04 | English | ||
| 31233143 | 4 Filing | 2026-02-04 | English | ||
| 31233276 | SCHEDULE 13G Filing | 2026-01-30 | English | ||
| 31233114 | 4 Filing | 2026-01-30 | English | ||
| 12952145 | 8-K | 2026-01-14 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
PRECISION BIOSCIENCES INC
Clinical-stage gene editing company developing therapies fo…
|
DTIL | US | Professional, scientific and te… |
|
Predictive Oncology Inc.
Applies AI and a biobank to predict drug response for oncol…
|
POAI | US | Professional, scientific and te… |
|
Predict S.p.A.
Develops and distributes AI medical solutions for imaging, …
|
PRE | IT | Professional, scientific and te… |
|
PRESCIENT THERAPEUTICS LIMITED
Clinical-stage oncology firm developing modular cell therap…
|
PTX | AU | Professional, scientific and te… |
|
PreveCeutical Medical
Health sciences company researching and developing innovati…
|
PREV | CA | Professional, scientific and te… |
|
ProMIS Neurosciences Inc.
Develops selective antibody therapeutics for neurodegenerat…
|
PMN | CA | Professional, scientific and te… |
|
Propanc Biopharma, Inc.
Clinical-stage company developing cancer treatments to prev…
|
PPCB | US | Professional, scientific and te… |
|
ProQR Therapeutics N.V.
Develops RNA therapies for severe genetic disorders using i…
|
PRQR | NL | Professional, scientific and te… |
|
Prostatype Genomics AB
Develops a genetic test that assesses prostate cancer aggre…
|
PROGEN | SE | Professional, scientific and te… |
|
Protagenic Therapeutics, Inc.\new
Develops peptide-based therapeutics for stress-related neur…
|
PTIX | US | Professional, scientific and te… |
Absci Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32931/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32931 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32931 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32931 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32931}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Absci Corp (id: 32931)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.